Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're right - I was thinking of cash.
It's too late to buy shares on the Record Date and get the dividend. You have to buy days before REcord Date to be shareholder of record on the record date because it takes days to transfer shares on the books. That's why people are selling today. The Sellers will get the new Regen shares. The new buyers today will not get Regen shares (unless they owned shares last week.
You are so right. The website has additional disclosure that must be considered. Without approval of the delivery system by FDA, DCTH doesn't really stand to benefit from Orphan Drug designation.
"This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company's future clinical trials including without limitation the HCC trials, FDA approval of the melphalan Delcath Hepatic Delivery System for the treatment of HCC,, the Company's ability to benefit from the orphan drug designation for melphalan for the treatment of HCC, the Company's ability to satisfy the requirements of the FDA's Complete Response Letter and provide the same in a timely manner, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, approval of the current or future chemosaturation system for delivery and filtration of melphalan, doxorubicin or other chemotherapeutic agents for various indications in the US and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into strategic partnership and distribution arrangements in foreign markets including Australia and key Asian markets and timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects ..."
Biomedics Rapid Relief Electronic Pain Relief Pad sounds very similar to Actipatch? Is it approved? It's advertised for sale at Walgreens and there's a coupon in the paper to purchase? Anyone know what the difference is? I haven't checked FDA site. Maybe we should let FDA know and complain? http://www.homedics.com/health/rapid-relief/rapid-relief-electronic-pain-relief-pad.html
I agree it's a good sensible combo and can be a superior product. I'm just saying Biel's "no drug" advertising will need to be modified. To have a patent for the combo is great. They now can tout being superior to other topicals like salonpas by saying we offer that AND the PEMF tech. Interested in seeing how the focus will change and it certainly can't hurt. People are very susceptive to suggestion and like to feel something to know it's working. Adding sensation of heat/cold/tingling is effective with effect of PEMF should sell better.
Thoughts on New Patent?
Excerpt below shows it includes a "drug". Advertisement for Biel Products show "no drug". Wonder if there is a plan to launch a new product or revise the current ones?
The new patent combines Pulsed Electromagnetic Field (PEMF) Technology with the combining of an adhesive that contains a therapeutic substance such as Salicylate, a Nicotinate Ester, Capsaicin, Isopropanol, Menthol or a combination thereof.
With Teva as a partner, good things could happen per Article below - The wait is tough but we may not have to wait until trial is concluded.
http://seekingalpha.com/article/1047301-buying-teva-s-immunotherapy-investment
Excerpts below:
Teva Pharmaceuticals (TEVA) is one of the behemoths in the pharmaceutical industry with a strategic commitment to the growing acceptance of immunotherapy as one line of treatment to combat cancer.
Teva's biotech partner does have a certified production facility (which truly is a rarity among microcap biotechs) and its patent estate offers years of protected revenue across the Americas, Europe, Asia, and Middle East. But I also think the Phase III clinical trial will be successfully halted sooner rather than later for the following reasons: (1) the death-rate of patients not treated with Multikine will conclude the clinical trial in advance of full enrollment, and (2) the repeated finding of regressed cancerous tumors will convince the FDA to render an early decision. However, if none of this happens, this relatively small price gamble will probably render results within the next few years.
Teva's investment is a strategic buy for that savvy investor who has done their homework on Multikine's tumor shrinking history. Yes, in my opinion, the clinical research also reported in scientific literature supports that contention -- that Multikine triggers an immuno-anti-cancer response when it is given per the directions of its inventors.
Investors who follow me know that I am a contrarian biotech investor. I am "long" until I sell though I never "short" stocks. The current case here seems almost too easy for me because the risk of overall loss ($2,900) is a drop in the bucket should Multikine be successful since I could earn six figures. Nevertheless, weigh the risk and seek the advice of a licensed market professional. In my view, Teva is the savvy investor because buying its biotech partner is a no-brainer. Quite frankly, most oncology stocks at this point in a Phase III clinical trial are being sold for $3-5/share.
Compassionate Use designation should've seen a huge spike. Hopefully, problem is that some weren't allowed to trade but now will. Unbelievable!
Cleared for Compassionate Use?! Great News! Need more people to be aware of AEMD to increase PPS.
Anyone have etrade? I am logged in and it shows NO activity in ambs yet you all are talking about buys? Are there?
MD Anderson Moon Shots-new program targeting certain types of cancer with new technology and immune system boosters. MCET's tech fits criteria. There's no info on biotech firms involved but we can hope....
http://www.mdanderson.org/newsroom/cancer-newsline/cancer-newsline-topics/2012/cancermoonshots-cnl.html
Very professional, impressive and informative video. So many possibilities to help people actually get well.
The spelling, grammar and sentence structure is not as good as usual. Was it a quick, get it out there since the stock is falling so bad? If 2 people hadn't posted, I would question the authenticity.
Your post is language coming from a separate company (not PWRM). Issue at hand is IP assets. Long story-trustee attempting to have the other company return the assets to IP so that they can be sold at auction. Also, another separate company has license for some technology and supposed to have option to purchase but since then I've seen in that company's disclosure no mention of success, so probably not going to happen. Power 3 is done. Chapter 7 - no 10Q - no restructuring - no assets will be available to the Shareholders because there are too many secured creditors.
Did anyone ever contact the VP sales and marketing for Biel last 2 years. He has a very impressive resume even if there aren't sales at Biel. He has over 23M shares. Wondering what his level of involvement is now?
Anron Horev
http://www.linkedin.com/pub/arnon-horev/4/566/784
Why would you do that? Etrade doesn't charge additional - no problem with trading BIEL.
BMSN owns ENTB and they had a great day - up $67%. About time something happens with these two.
Bankruptcy update - They probably won't file the 10Q. They file Stmt of Financial Affairs in Bankruptcy court which shows all assets/liabilities and obligations. They had $277 in bank and no other assets other than shares of Amarantus which were given in exhange for license. Amarantus has now made an appearance in the Court requesting NOtices. What has happened is the Trustee is trying to void the transfer of the IP assets to Neogenomics or return of $241K in value because it occurred within 90 days prior to filing of bankruptcy. This is Bankruptcy Law and is typical and the Trustee probably will get this granted. That means that $$ would be used in the Court to pay the Secured Creditors and Neogenomics would have to again present the Judgment to get the assets or the $$. In any event, there still be no $$ for shareholders - what it would do is allow the owners of PWRM to perhaps get some of their claim which is annoying. One thing for certain - the lawyers, accountants and trustee will get paid. The Docket still shows no Date for Proof of Claim. there probably won't be one set. Typically in a Chapter 7, Proof of Claims are not allowed to be submitted because there is no $$ to disperse. If there was, the company would've filed a Chapter 11. sometimes a Chapter 7 does find $$ and states a date to file a POC but again - the shareholders are at the bottom of the list - there won't be anything. Only way there would be is if the IP was given back to PWRM and they were allowed to find a new buyer and brought in several million $$. However, Neogenomics will have a good standing. Plus Amarantus is probably not too happy with the fact that it traded its shares for a license in question? Not good.
DowB82 pumping and duping others on MOMO and BB Stock Haven Boards and for chance to get $100 on an uptick of .0001 for 1M shares. Amazing. Piddly profit knowing the end will come without warning. Be prepared for the day you buy at .0013 and can't dump any of it.
If they hadn't been evicted, I could consider popping over to give them a piece of my mind. The nerve!
IP assets transferred to Neogenomics Mar 7 towards payment of Judgment. (Makes sense now why they filed Chap 7 on Mar 15-they have no assets.) There is still a balance due. Receivorship below shows all patents that were transferred. There are also other lawsuits and secured creditors, including IRS and law firms. Helen Park and Ira are each co-debtors but also are in top 20 unsecured creditors. They are owed $439K and $169K respectively. PWRM has $866,422 in assets and $3,732,046 in Liabilities. After Secured Creditors and judgments, nothing for Shareholders.
From Neogenomics 10K http://sec.gov/Archives/edgar/data/1077183/000119312512109860/d262716d10k.htm
Power3 Medical Products Intellectual Property
In April 2007, we entered into an agreement with Power3 Medical Products, Inc., (“Power3”), an early stage company engaged in the discovery, development, and commercialization of protein biomarkers, regarding the formation of a joint venture contract research organization. As part of the agreement, we provided $200,000 of working capital to Power3 by purchasing a 6% convertible debenture, due April 17, 2009 (the “Debenture”). During the year-ended December 31, 2008 we booked an impairment charge against the full value of our investment in the Power3 Debenture due to the uncertainty of its collectability. In April 2009, we notified Power3 that it was in default of its obligations under the Debenture for failing to pay interest on the Debenture since September 2008 and for failing to pay principal when due.
In March 2010, we filed a complaint in the New York State Supreme Court in New York County to recover the principal, interest and other fees and expenses due and owing to us. In December 2010, the Supreme Court of the State of New York issued a judgment against Power3 in favor of NeoGenomics in the amount of $241,127. In September 2011, we intervened in an existing court-appointed Receivership against Power3 in the District Court of Harris County, Texas.
On February 23, 2012, the Receiver held an auction of Power3’s assets pursuant to a court order. At such auction, we credit bid our entire judgment amount for certain intellectual property assets of Power3, which included pending patents related to certain protein biomarkers which may be useful in the diagnosis of breast cancer and neurodegenerative disease. The Receiver in this action accepted our bid and gave Power3 until March 7, 2012 to pay off our judgment in full. On March 7, 2012 the judgment was not paid and ownership of nineteen pending patents and one issued patent was transferred to NeoGenomics
Copy of receivership doc filed in BK case is converted from pdf to Word so a little jumbled. PWRM has $866,422 in assets and $3,732,046 in Liabilities. NO. 850,456-401
KFORCEINC. §
§
IN THE COUNTY CIVIL COURT
vs. §
§
POWER 3 MEDICAL PRODUCTS, INC. §
AT LAW NO FOUR (4)
HAJ<UUSCOUNTY,TEXAS
RECEIVER'S STATUS REPORT
AND NOTES, AND ACCOUNTING REGARDING THE COURT AUTHORIZED SALE OF INTELLECTUAL PROPERTY
Comes Now, Henry Radoff, your Receiver, and provides the Court with this status report regarding the sale of certain intellectual property including patent applications and a patent held in custodia legis in the Receivership Estate of Power 3 Medical Products, Inc.
1. Out of Comiesy, the Defendant was Given until March 7, at 5 PM to make good on its settlement agreement in !<force, Inc.and, in addition to pay the amount due the Receiver in the Neogenomics Inc. Intervention if Defendant wished to redeem the intellectual property.
2. Defendant did not communicate by telephone, email, fax or any other method of conm1tmication regarding its intention to redeem. Neither Ms. Park nor any other
. .. . represe11tativeofPowerJ showed up_ by the agreed-upon redemption deadline.
3. Accordingly, as reported in my previous status report, I noted the redemption period had expired,and,finalized the sale to Neogenomics, Inc. Neogenomics bid for $241,127.00 bad been accepted on February 23, 2012 as the highest bid. After the redemption period expired, and as per the Receiver's agreement with Power 3 Medical Products, Inc. I then transferred ownership of the intellectual property to Neogenomics via USPTO website.
OFFICIAL ACCOUNTING & CREDITS TO THE JUDGMENT
Neogenomics payment was in the form of a bid of credits against the existing judgment it holds against Power 3. As previously agreed, Receiver was not entitled to any type of fee from Neogenomics in the event that credits were exclusively used to bid at the sale. For final accounting of the Neogenomics Intervention, Power 3 Medical Products received a credit of $241,127 against is debt to Neogenomics, and the Receiver did not receive any portion of the sale price nor any proceeds from the b:ansaction.
This concludes Your Receiver's participation in the sale of the intellectual property, with all documents reflecting the events which transpired before, during, and after the sale documented and
filed with the Court for reference.
Attached to this Status report is the documentation from the USPTO approving the transfer of the intellectual property by Receiver's Sale pursuant to this Court's order.
Respectfully Submitted,
Heruy V. Radoff
Court Appointed Receiver
1800 Bering, Suite 315
Houston, Texas 77057
713-521-0910 phone
713-599- 178 facsimile
713-599-1177 phone
713-599-1178 facsimile
UNITED STATES PATENT AND TRADEMARI{ OFFICE
UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE
MARCH 12, 2012
JON MALONE, SPECIAL COUNSEL TO RECEIVER
1800 BERING SUITE 315
HOUSTON, TX 77057
PTAS
501845377
UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.
PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX
1450, ALEXANDRIA, VA 22313.
RECORDATION DATE: 03/07/2012 REEL/FRAME: 027831/0109
NUMBER OF PAGES: 26
BRIEF: SALE BY COURT RECEIVER
ASSIGNOR:
THE RECEIVERSHIP ESTATE OF POWER 3
MEDICAL PRODUCTS, INC.
DOC DATE: 02/23/2012
ASSIGNEE:
NEOGENOMICS, INC. AKA NEOGENOMICS LABORATORIES
12701 COMMONWEALTH DRIVE SUITE 5
FORT MEYERS, FLORIDA 33913
APPLICATION NUMBER: 09088329 FILING DATE: 06/01/1998
PATENT NUMBER: 6148297 ISSUE DATE: 11/14/2000
TITLE: HEALTH CARE INFORMATION AND DATA TRACKING SYSTEM AND METHOD
APPLICATION NUMBER: 10931333 FILING DATE: 09/01/2004
PATENT NUMBER: ISSUE DATE:
TITLE: ACETYL-LDL RECEPTOR AS A BIOMARKER FOR BREAST CANCER
E hibit
P.O.Box 1450, Alexandria, Vlrnla 22313-1450- WWW.USPTO.GOV
APPLICATION NUMBER: 11038753 FILING DATE: 01/19/2005
PATENT NUMBER: ISSUE DATE:
TITLE: ACETYL-LDL RECEPTOR RELATED PROTEINS AND PEPTIDES AS A BIOMARKER
FOR NEURODEGENERATIVE DISEASE
APPLICATION NUMBER: 11038754 FILING DATE: 01/19/2005
PATENT NUMBER: ISSUE DATE:
TITLE: FK506-BINDING PROTEIN 7 RELATED PROTEIN AS A BIOMARKER FOR
NEURODEGENERATIVE DISEASE
APPLICATION NUMBER: 11039005
PATENT NUMBER:
FILING DATE: 01/19/2005
ISSUE DATE:
TITLE: 21 -51 -0LIGOADENYLATE SYNTHETASE LIKE PROTEIN AS A BIOMARKER FOR NEURODEGENERATIVE DISEASE
APPLICATION NUMBER: 11039600
PATENT NUMBER:
FILING DATE: 01/19/2005
ISSUE DATE:
TITLE: TRIM 5 RELATED DISEASE
PROTEIN AS A BIOMARKER OF NEURODEGENERATIVE
APPLICATION NUMBER: 11172219 FILING DATE: 06/29/2005
PATENT NUMBER: ISSUE DATE:
TITLE: DIFFERENTIAL PROTEIN EXPRESSION PATTERNS RELATED TO DISEASE STATES
APPLICATION NUMBER: 11179740
PATENT NUMBER:
TITLE: ANTIBODY-BASED SYSTEM EXPRESSION PATTERNS
FILING DATE: 07/12/2005
ISSUE DATE:
FOR DETECTION OF DIFFERENTIAL PROTEIN
APPLICATION NUMBER: 11411659 FILING DATE: 04/26/2006
PATENT NUMBER: ISSUE DATE: TITLE: ASSAY FOR NEUROMUSCULAR DISEASES;"
APPLICATION NUMBER: 11487715 FILING DATE: 07/17/2006
PATENT NUMBER: ISSUE DATE:
TITLE: ASSAY FOR ALS AND ALS-LIKE DISORDERS
APPLICATION NUMBER: 11503881
PATENT NUMBER:
FILING DATE: 08/14/2006
ISSUE DATE:
TITLE: ASSAY FOR DISORDERS
DIFFERENTIATING ALZHEIMER'S AND ALZHEIMER 1 S-LIKE
APPLICATION NUMBER: 11507337 FILING DATE: 08/21/2006
PATENT NUMBER: ISSUE DATE:
TITLE: ASSAYS FOR DIAGNOSIS EMPLOYING BLOOD SERUM PROTEIN BIOMARKERS
BETWEEN PARKINSON'S AND PARKINSON'S-LIKE DISEASE
APPLICATION NUMBER: 11635281
PATENT NUMBER:
FILING DATE: 12/07/2006
ISSUE DATE:
TITLE: TWELVE {12) PROTEIN OF BREAST CANCER
BIOMARKERS FOR DIAGNOSIS AND EARLY DETECTION
APPLICATION NUMBER: 11731019 FILING DATE: 03/29/2007
PATENT NUMBER: ISSUE DATE:
TITLE: ACTIN PROTEINS AS BIOMARKERS FOR INDICATION AND TARGETING OF
RESISTANCE AND SENSITIVITY TO AN ABL KINASE INHIBITOR IN
PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
APPLICATION NUMBER: 11897078 FILING DATE: 08/29/2007
PATENT NUMBER: ISSUE DATE:
TITLE: COMPLEMENT FACTOR H PROTEIN AS A BIOMARKER OF PARKINSON'S DISEASE
APPLICATION NUMBER: 11899212
PATENT NUMBER:
FILING DATE: 09/05/2007
ISSUE DATE:
TITLE: APOLIPOPROTEIN DISEASE
E3 PROTEIN AS A BIOMARKER OF NEURODEGENERATIVE
APPLICATION NUMBER: 12217885 FILING DATE: 07/08/2008
PATENT NUMBER: ISSUE DATE:
TITLE: MULTIPLE FORMS OF ALZHEIMER'S DISEASE BASED ON DIFFERENCES IN CONCENTRATIONS OF PROTEIN BIOMARKERS IN BLOOD SERUM
APPLICATION NUMBER: 12313136 FILING DATE: 11/17/2008
PATENT NUMBER: ISSUE DATE:
TITLE: IDENTITIES, SPECIFICITIES, AND USE OF TWENTY TWO (22)
DIFFERENTIALLY EXPRESSED PROTEIN BIOMARKERS FOR BLOOD BASED DIAGNOSIS OF BREAST CANCER
APPLICATION NUMBER: 12313139
PATENT NUMBER:
FILING DATE: 11/17/2008
ISSUE DATE:
TITLE: ISOFORM SPECIFICITIES OF BLOOD SERUM PROTEINS AND THEIR USE AS
DIFFERENTIALLY EXPRESSED BREAST CANCER
PROTEIN BIOMARKERS FOR DIAGNOSIS OF
APPLICATION NUMBER: 12802630 FILING DATE: 06/10/2010
PATENT NUMBER: ISSUE DATE:
TITLE: DIAGNOSIS OF PARKINSON'S DISEASE
ASSIGNMENT RECORDATION BRANCH PUBLIC RECORDS DIVISION
Wow! I had no idea that it could aid in bone growth. I wonder if that could be used in place of drugs like fosamax and boniva for osteoporosis? They can have bad side-effects so if the PEMF can be used, that would be great.
Yeah-I certainly wish it was otherwise. Had alot of hope for this one. A Chap 11 would've been a cross your fingers & maybe they'll reorg and have something left. But with a 7, even the secured creditors don't get their $$. Lawyers and the Court get it first. People that are saying otherwise either know nothing about bankruptcy or are trying to dupe others into buying so they can sell a bit higher. If the latter, I hope they crash when the door shuts all of a sudden.
I'm not able to copy the Original Petition that was filed but it shows $500K - $1M in assets and $1M - $10M in Liabilities.
The Debtor (PWRM) checked the following box.
Debtor estimates that, after any exempt property is excluded and administrative expenses paid,there will be no funds available for distribution to unsecured creditors.
Shareholders are at the bottom of the list of "unsecured creditors". If there would've been any hope, they would've filed Chapter 11.
Notice to Creditors - Typical of Chapter 7 stating DON'T File a claim - there are no assets.
B9B (Official Form 9B) (Chapter 7 Corporation/Partnership No Asset Case) (12/11) Case Number 12-32024
UNITED STATES BANKRUPTCY COURT District of Southern District of Texas
Notice of
Chapter 7 Bankruptcy Case, Meeting of Creditors, & Deadlines
A chapter 7 bankruptcy case concerning the debtor(s) listed below was filed on 3/15/12.
You may be a creditor of the debtor. This notice lists important deadlines. You may want to consult an attorney to protect your Rights. All
documents filed in the case may be inspected at the bankruptcy clerk's office at the address listed below. NOTE: The staff of the bankruptcy
clerk's office cannot give legal advice.
See Reverse Side For Important Explanations
Debtor(s) (name(s) used by the debtor(s) in the last 8 years, including married, maiden, trade, and address):
Power3 Medical Products, Inc
26202 Oakridge Drive, Ste. A102
Spring, TX 77380
Case Number:
12-32024
Taxpayer ID/Employer ID/Other Nos.:
65-0565144
Attorney for Debtor(s) (name and address):
Julie Mitchell Koenig
Tow & Koenig, PLLC
26219 Oak Ridge Drive
The Woodlands, TX 77380
Telephone number: 281-681-9100
Bankruptcy Trustee (name and address):
Lowell T Cage
Cage Hill and Niehaus LLP
5851 San Felipe
Suite 950
Houston, TX 77057
Telephone number: 713-789-0500
Meeting of Creditors
Date: April 12, 2012 Time: 02:00 PM
Location: Suite 3401, 515 Rusk Ave, Houston, TX 77002
Creditors May Not Take Certain Actions:
In most instances, the filing of the bankruptcy case automatically stays certain collection and other actions against the debtor and the
debtor's property. Under certain circumstances, the stay may be limited to 30 days or not exist at all, although the debtor can request the
court to extend or impose a stay. If you attempt to collect a debt or take other action in violation of the Bankruptcy Code, you may be
penalized. Consult a lawyer to determine your rights in this case.
Please Do Not File a Proof of Claim Unless You Receive a Notice To Do So.
Creditor with a Foreign Address:
A creditor to whom this notice is sent at a foreign address should read the information under "Do Not File a Proof of Claim at This Time"
on the reverse side.
Address of the Bankruptcy Clerk's Office:
United States Bankruptcy Court
PO Box 61010
Houston, TX 77208
Telephone number: (713) 250-5500
For the Court:
Clerk of the Bankruptcy Court:
David J. Bradley
Hours Open: Monday - Friday 9:00 AM - 5:00 PM Date: 3/22/12
EXPLANATIONS B9B (Official Form 9B) (12/11)
Filing of Chapter 7
Bankruptcy Case
A bankruptcy case under Chapter 7 of the Bankruptcy Code (title 11, United States Code) has been filed in this court
by or against the debtor(s) listed on the front side, and an order for relief has been entered.
Legal Advice The staff of the bankruptcy clerk's office cannot give legal advice. Consult a lawyer to determine your rights in this
case.
Creditors Generally
May Not Take Certain
Actions
Prohibited collection actions are listed in Bankruptcy Code §362. Common examples of prohibited actions include
contacting the debtor by telephone, mail or otherwise to demand repayment, taking actions to collect money or
obtain property from the debtor; repossessing the debtor's property; and starting or continuing lawsuits or
foreclosures. Under certain circumstances, the stay may be limited to 30 days or not exist at all, although the debtor
can request the court to extend or impose a stay.
Meeting of Creditors A meeting of creditors is scheduled for the date, time and location listed on the front side. The debtor's
representative must be present at the meeting to be questioned under oath by the trustee and by creditors. Creditors
are welcome to attend, but are not required to do so. The meeting may be continued and concluded at a later date
specified in a notice filed with the court.
Do Not File a Proof of Claim at This TimeThere does not appear to be any property available to the trustee to pay creditors. You therefore should not file a
proof of claim at this time. If it later appears that assets are available to pay creditors, you will be sent another notice
telling you that you may file a proof of claim, and telling you the deadline for filing your proof of claim. If this
notice is mailed to a creditor at a foreign address, the creditor may file a motion requesting the court to extend the
deadline.
Bankruptcy Clerk's
Office
Any paper that you file in this bankruptcy case should be filed at the bankruptcy clerk's office at the address listed
on the front side. You may inspect all papers filed, including the list of the debtor's property and debts and the list of
the property claimed as exempt, at the bankruptcy clerk's office.
Creditor with a
Foreign Address
Consult a lawyer familiar with United States bankruptcy law if you have any questions regarding your rights in this
case.
Refer to Other Side for Important Deadlines and Notices
SEC on Bankruptcy http://www.sec.gov/investor/pubs/bankrupt.htm
Chap 7 doesn't have to notify shareholders (Chap 11 does); trading doesn’t have to be halted. Business continues “as usual” until doors are shut. There will be Creditors mtg April 12, but it won’t matter. Currently, it says “do not file claim”. That is because there are no assets. If assets are found (which they won’t be, the Shareholder will be able to file but they’re at bottom of list –will get nothing. So those that are buying now will all of a sudden find they own stock of a company that no longer exists and have no recourse. See SEC excerpt below
What is Chapter 7 Bankruptcy?
Some companies are so far in debt or have other problems so serious that they can't continue their business operations. They are likely to "liquidate" and file under Chapter 7. Their assets are sold for cash by a court appointed trustee. Administrative and legal expenses are paid first, and the remainder goes to creditors. Secured creditors will have their collateral returned to them. If the value of the collateral is not sufficient to repay them in full, they will be grouped with other unsecured creditors for the rest of their claim. Bondholders, and other unsecured creditors, will be notified of the Chapter 7, and should file a claim in case there's money left for them to receive a payment.
Stockholders do not have to be notified of the Chapter 7 case because they generally don't receive anything in return for their investment. But, in the unlikely event that creditors are paid in full, stockholders will be notified and given an opportunity to file claims.
Does My Stock or Bond Have Any Value?
Usually, the stock of a Chapter 7 company is worthless and you have lost the money you invested.
Chap 11 is used by companies a lot to "reorganize" and get rid of debt. PWRM doesn't qualify for Chap 11 - no assets-nothing to reorganize-nobody will fund them so they had to file Chap 7. There's no hope of redemption. Close the door - Shareholders lose all. Very upsetting - I live in the Woodlands, near where they are and really was pushing for PWRM. They should've handled it differently and tried for a Chap 11 instead of draining everything first at Shareholders' expense.
Chapter 7 means Dead - No assets - lots of obligations. Chapter 11 is okay - That would be Reorg time BUT this is chapter 7 - Not a prayer. People don't know PWRM is in bankruptcy -
Nice site w good info - not sure if Biel owns it or investor owned?
http://bielstock.com/
I sent the following - see what kind of response I get. Plus, how can it still be sold on Amazon?
You rec’d a Warning letter from FDA on Jan 31 but didn’t include in your FDA Status update or in any way notify investors – why is that? Both the FDA letter and your Response should've been provided to Investors.
You can't lose more than 100% of the amt you have invested but a stock can lose more than 100% of its starting value.It's called reverse split. A stock selling for $1 that does a reverse split of 1 for 100 becomes worth 1 cent per share. Reverse split doesn't affect the overall $ value of a portfolio but it definintely affects the value of a share. The share is now worth only 1/100 of what it was worth. So now if that one share goes up 100%, it's only worth 2 cents. It would have to go up 10,000% to get back to $1.
Very promising. Great update.
http://aethlonmedical.investorroom.com/index.php?s=19
Why the sudden drop? What happened?
New Shareholder letter - Potential Partners
http://aethlonmedical.investorroom.com/index.php?s=43&item=80
To our Shareholders:
On April 1st, we submitted a contract response to the Defense Advanced Research Projects Agency (DARPA) related to the Dialysis Like Therapeutics (DLT) program referenced in my last shareholder letter. In our submission, we proposed to leverage our technology platform to deliver a dialysis-like therapy that would address precursors to sepsis, including bacterial toxins, viral pathogens, and disease enhancing particles transported by exosomes. We believe our proposal meets goals underlying the DLT program as the resulting device would target to reduce the occurrence of sepsis and would provide decision-free and life saving medical care for the wounded warfighter. Additionally, we introduced an innovative strategy to deliver our dialysis-like therapy without the need for anticoagulants, as well as a novel approach to selectively clear whole bacteria from circulation.
If selected for an award, several larger organizations and industry thought leaders have agreed to partner with us to advance our program proposals. It is anticipated that the DLT program awards will be announced in the next 120 days. We are now collaborating with our advisors to determine the next contract or grant opportunity to pursue. Beyond non-dilutive bioterror and pandemic threat funding opportunities, we are also evaluating potential responses to new government programs in Hepatitis-C, HIV, and Cancer.
In addition to navigating government funding opportunities, we are actively advancing research and clinical initiatives in both infectious disease and cancer. On the clinical front, I am pleased to disclose that we our close to submitting our updated IDE to the FDA. The goal of our submission is approval from the FDA to initiate Hemopurifier(R) human studies in the United States. Details regarding our FDA communications and clinical site locations can be expected through forthcoming news disclosures.
In regards to our HCV treatment study in India, we initiated treatment of our first patient at the Medanta Medicity Institute, which was observed by our President, Rod Kenley. In previous studies, we demonstrated significant viral load reductions in health compromised dialysis patients that were infected with either HCV or HIV. In this study, we are leveraging those results to demonstrate that our Hemopurifier(R) can accelerate viral load reduction when administered to non-dialysis patients in combination with drug therapy. Based on a prior clinical validation, we are confident in our capabilities and recognize the potential significance of our Hemopurifier(R) as viral load depletion rates in the earliest stages of therapy are considered predictive of patients who achieve long-term clinical benefit. In the treatment of our first patient, it was recognized early on that that we needed to modify our protocol to administer anticoagulants in dosages specific to our therapy, and not in amounts normally administered to dialysis patients. Regardless, there was no harm to this patient, although the anticoagulant miscalculation did not allow him to successfully complete his entire treatment. While causing a delay of several weeks, our protocol has been formally amended and we are now ramping up patient enrollment. We are also seeking to open up our study to those residing outside of India, based on worldwide inquiries from infected individuals.
In closing, I also wish to disclose that Jeff Richardson has agreed to rejoin our team on a part-time basis. While you may or may not recall Jeff, he was responsible for originating national news coverage our technology through multiple media outlets, including Popular Science, CNN, and Readers Digest. As the former communications director at Amgen, Jeff provides tremendous insight on advancing the awareness of innovative medical therapies through the national media.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Lilly says FDA denies nod to dye for Alzheimer's test
http://www.reuters.com/article/2011/03/18/elililly-idUSL3E7EI1QU20110318
could be good opportunity for PWRM if they hurry up and get moving!!
Lawsuit is in re GA corp - Multicell Inc fka Multiplexhttp://corp.sos.state.ga.us/corp/soskb/Corp.asp?1682860
Business Name History
--------------------------------------------------------------------------------
Name Name Type
MULTICELL, INC. Current Name
--------------------------------------------------------------------------------
Profit Corporation - Domestic - Information
Control No.: 10047631
Status: Active/Compliance
Entity Creation Date: 6/30/2010
Jurisdiction: GA
Principal Office Address: 4744 NORTH ROYAL ATLANTA DRIVE, SUITE C
Tucker GA 30084
Last Annual Registration Filed Date: 2/13/2011
Last Annual Registration Filed: 2011
--------------------------------------------------------------------------------
Registered Agent
Agent Name: Salazar, Sandra A
Office Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
Agent County: Dekalb
--------------------------------------------------------------------------------
Officers
Title: CEO
Name: Sandra A Salazar
Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
--------------------------------------------------------------------------------
Title: CFO
Name: Sandra A Salazar
Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
--------------------------------------------------------------------------------
Title: Secretary
Name: Sandra A Salazar
Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
Multicell Technologies is a DE corp
corp.delaware.gov/
File Number: 0750330 Incorporation Date / Formation Date: 04/28/1970
(mm/dd/yyyy)
Entity Name: MULTICELL TECHNOLOGIES, INC.
Entity Kind: CORPORATION Entity Type: GENERAL
Residency: DOMESTIC State: DE
REGISTERED AGENT INFORMATION
Name: CORPORATION SERVICE COMPANY
Address: 2711 CENTERVILLE ROAD SUITE 400
City: WILMINGTON County: NEW CASTLE
State: DE Postal Code: 19808
Phone: (302)636-5401
Lawsuit is in re GA corp - Multicell Inc fka Multiplexhttp://corp.sos.state.ga.us/corp/soskb/Corp.asp?1682860
Business Name History
--------------------------------------------------------------------------------
Name Name Type
MULTICELL, INC. Current Name
--------------------------------------------------------------------------------
Profit Corporation - Domestic - Information
Control No.: 10047631
Status: Active/Compliance
Entity Creation Date: 6/30/2010
Jurisdiction: GA
Principal Office Address: 4744 NORTH ROYAL ATLANTA DRIVE, SUITE C
Tucker GA 30084
Last Annual Registration Filed Date: 2/13/2011
Last Annual Registration Filed: 2011
--------------------------------------------------------------------------------
Registered Agent
Agent Name: Salazar, Sandra A
Office Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
Agent County: Dekalb
--------------------------------------------------------------------------------
Officers
Title: CEO
Name: Sandra A Salazar
Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
--------------------------------------------------------------------------------
Title: CFO
Name: Sandra A Salazar
Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
--------------------------------------------------------------------------------
Title: Secretary
Name: Sandra A Salazar
Address: 3326 Landsburry Village Drive #4
Atlanta GA 30341
Multicell Technologies is a DE corp
corp.delaware.gov/
File Number: 0750330 Incorporation Date / Formation Date: 04/28/1970
(mm/dd/yyyy)
Entity Name: MULTICELL TECHNOLOGIES, INC.
Entity Kind: CORPORATION Entity Type: GENERAL
Residency: DOMESTIC State: DE
REGISTERED AGENT INFORMATION
Name: CORPORATION SERVICE COMPANY
Address: 2711 CENTERVILLE ROAD SUITE 400
City: WILMINGTON County: NEW CASTLE
State: DE Postal Code: 19808
Phone: (302)636-5401
Not the same company
Very positive presentation - so many comparisons to DNDN but NWBO sounds even more promising. Sooo hard to wait!!
Power 3 a part of this? They presented at same conference and have licensing agmt w Baylor.
http://www.deseretnews.com/article/700050607/Texans-near-an-Alzheimers-blood-test.html
Texans near an Alzheimer's blood test
By Todd Ackerman
Houston Chronicle
Published: Sunday, July 25, 2010 9:41 a.m. MDT
HOUSTON — Texas scientists are on the verge of developing a blood test to identify patients with Alzheimer’s disease, a potential major breakthrough in the still difficult-to-diagnose ailment.
The test, details of which were presented at an international conference on Alzheimer’s in Hawaii this month, would give non-specialists who often have trouble diagnosing the devastating disease a tool to catch it earlier and make a referral when its progression can still be slowed.
“If it’s confirmed, this test will offer millions of geriatric patients across the country and the planet the opportunity at least to be screened annually,” said Dr. Sid O’Bryant, a professor of neurology at Texas Tech Health Sciences Center and the primary investigator of the study reported in Hawaii. “Then, if it’s positive they can go to a specialist and get a proper workup and start treatment.”
The test, which measures a mix of more than 100 blood proteins, accurately classified those participants who had the disease and those who didn’t 95 percent of the time. Blood samples were taken from about 600 people, split between those with and without the disease.
Many research teams are pursuing such a diagnostic tool, but Baylor College of Medicine team member Dr. Rachelle Doody said the Texas research is the most comprehensive and furthest along. The Texas team will publish a paper on the study in an undisclosed journal this fall, only the second ever such journal publication involving an Alzheimer’s blood test.
Doody stressed that the study still needs to be replicated. The team has submitted a grant request to the National Institutes of Health that would not only attempt to replicate the results, but also assess its ability to distinguish different types of Alzheimer’s and to predict people’s risk of developing the disease.
More than 5 million Americans have the degenerative brain disease, according to the Alzheimer’s Association, and experts predict the number will double over the next 15 years as baby boomers age. Texas has 340,000 people with Alzheimer’s or other forms of dementia, an amount projected to grow to at least half a million by 2025.
The study was the product of the Texas Alzheimer’s Research Consortium, a Legislature-created collaboration comprised of Baylor, Texas Tech, the University of Texas Southwestern Medical Center in Dallas, the UT Health Science Center at San Antonio and the University of North Texas Health Science Center in Fort Worth.
The consortium estimates that the value of unpaid care for Texas Alzheimer’s and dementia patients was $11.2 billion in 2009.
The biggest news at the Hawaii conference was a small company’s new brain scan for detecting plaque, the hallmark physical sign of Alzheimer’s disease. But O’Bryant noted that test requires PET scans not easily accessible to most seniors.
O’Bryant said specialists have become adept at detecting Alzheimer’s at an early stage, but many seniors get to them too late for helpful treatment because their first symptoms are often dismissed by primary-care doctors as age-related forgetfulness. A blood test available to all would change that.
O’Bryant’s team looked at patients whose Alzheimer’s and lack of Alzheimer’s was diagnosed using standardized criteria - neuroimaging, bloodwork, neuropsychological testing and neurological exams. They found that proteins in Alzheimer’s patients’ blood serum revealed a kind of signature for the disease, 25 biomarkers consistently differentiating Alzheimer’s from normal.
Doody said a research team from Australia using a different methodology had overlapping results, with many but not all of the same 25 proteins showing up in Alzheimer’s patients.
In addition, a University of North Carolina researcher and consultant to the Texas consortium presented data that showed changes in the genes reflected the distinguishing biomarkers.
The mix of proteins and complementary genetic data contrast with previous failed blood tests, which usually relied only on one protein.
“This test is going to work,” O’Bryant said. “We’ll add other biomarkers and continue to refine it and improve it, but it’s held too strong for it to be simply working by chance.”
Anyone know why the website is down?